Despite current therapeutic strategies for immunomodulation and relief of symptoms in
multiple sclerosis (MS), remyelination falls short due to dynamic neuropathologic …

The consistency, efficacy, and safety of cannabis-based medicines have been demonstrated
in humans, leading to the approval of the first cannabis-based therapy to alleviate spasticity …

The cannabis plant contains up to 110 cannabinoids, though Δ9-tetrahydrocannabinol
(THC) and cannabidiol (CBD) have been the primary focus of medical investigation. THC …

Multiple sclerosis is the predominant autoimmune disorder affecting the central nervous
system in adolescents and adults. Specific treatments are categorized as disease-modifying …

Background: As far as 80% of people diagnosed with multiple sclerosis (MS) experience
disabling symptoms in the course of the disease, such as spasticity and neuropathic pain. As …

There is increasing interest in the therapeutic potential of cannabis-based medicinal extracts
in multiple sclerosis. Cognitive deficits that have been attributed to long-term heavy …

Use of cannabis as a medicine for numerous conditions has a well-documented history
stretching back thousands of years. With the identification of an endogenous system of …

Abstract Purpose of Review Pharmaceutical cannabinoids such as nabiximols, nabilone and
dronabinol, and plant-based cannabinoids have been investigated for their therapeutic …

Multiple sclerosis (MS) is the major immune-mediated, demyelinating, neurodegenerative
disease of the central nervous system. Compounds within cannabis, notably Δ9 …

Importance Cannabinoids have antispastic and analgesic effects; however, their role in the
treatment of multiple sclerosis (MS) symptoms is not well defined. Objective To conduct a …